Literature DB >> 1329338

Evidence of human polyomavirus BK and JC infection in normal brain tissue.

C Elsner1, K Dörries.   

Abstract

Infection with the polyomaviruses JC and BK is ubiquitous in the human population and JCV is the only virus associated with the central nervous system disease progressive multifocal leukoencephalopathy. In the attempt to analyze the pathogenesis of polyomavirus infections we asked whether human polyomaviruses invade the brain during persistence. Brain autopsy material from 67 individuals with disorders other than PML was examined for the presence of polyomavirus DNA. Southern blot analysis demonstrated JCV-specific full-length virus genomes in healthy brain tissue in about 20% of the patients. Type-specific analysis with polymerase chain reaction and sequencing confirmed these data. Additionally, the presence of BKV DNA sequences covering an early gene fragment and the control region with flanking early and late protein coding sequences was detected. Cloning of the complete BKV genome from two cases supported the assumption that not only full-length JCV DNA was present in those tissue specimens but also BKV genomes. The data obtained demonstrate that dual infection of the brain with the polyomaviruses JCV and BKV is a common event and give strong evidence that both viruses frequently establish a latent CNS infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329338     DOI: 10.1016/0042-6822(92)90167-n

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  59 in total

1.  Detection of BK polyomavirus genotypes in healthy and HIV-positive children.

Authors:  C Di Taranto; V Pietropaolo; G B Orsi; L Jin; L Sinibaldi; A M Degener
Journal:  Eur J Epidemiol       Date:  1997-09       Impact factor: 8.082

2.  Role for tumor necrosis factor-α in JC virus reactivation and progressive multifocal leukoencephalopathy.

Authors:  Hassen S Wollebo; Mahmut Safak; Luis Del Valle; Kamel Khalili; Martyn K White
Journal:  J Neuroimmunol       Date:  2010-12-24       Impact factor: 3.478

3.  Natalizumab in the treatment of multiple sclerosis.

Authors:  Ozgür Yaldizli; Norman Putzki
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

4.  Microarray analysis of glial cells resistant to JCV infection suggests a correlation between viral infection and inflammatory cytokine gene expression.

Authors:  Kate Manley; Gretchen V Gee; Carl P Simkevich; John M Sedivy; Walter J Atwood
Journal:  Virology       Date:  2007-06-06       Impact factor: 3.616

5.  Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A.

Authors:  Moti L Chapagain; Saguna Verma; Frederic Mercier; Richard Yanagihara; Vivek R Nerurkar
Journal:  Virology       Date:  2007-03-30       Impact factor: 3.616

6.  The 50th birthday of progressive multifocal leukoencephalopathy: New insights into pathogenesis.

Authors:  Kenneth L Tyler
Journal:  Ann Neurol       Date:  2008-10       Impact factor: 10.422

Review 7.  The role of polyomaviruses in human disease.

Authors:  Mengxi Jiang; Johanna R Abend; Silas F Johnson; Michael J Imperiale
Journal:  Virology       Date:  2008-11-07       Impact factor: 3.616

8.  Propagation of archetype and nonarchetype JC virus variants in human fetal brain cultures: demonstration of interference activity by archetype JC virus.

Authors:  Frank J O'Neill; John E Greenlee; Kristina Dörries; Susan A Clawson; Helen Carney
Journal:  J Neurovirol       Date:  2003-10       Impact factor: 2.643

9.  Identical rearranged forms of JC polyomavirus transcriptional control region in plasma and cerebrospinal fluid of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy.

Authors:  Cesare Giovanni Fedele; Maria Rosa Ciardi; Salvatore Delia; Gerardo Contreras; José Luis Perez; Maria De Oña; Elisa Vidal; Antonio Tenorio
Journal:  J Neurovirol       Date:  2003-10       Impact factor: 2.643

10.  JCV detection in multiple sclerosis patients treated with natalizumab.

Authors:  Saud A Sadiq; Lauren M Puccio; Edward W A Brydon
Journal:  J Neurol       Date:  2010-01-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.